|
|
|
Contact Us
For contact click to e-mail
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Osamah Husseib , MD DEPARTMENT HEAD
|
|
Date : 13/11/2009
RESUME
Osamah Hussein
Identification or passport number: 55226419
Date and place of birth: 19/11/1958, Ramah Village, Israel
Marital Status: Married, 4 children
E mail: osama.h@ziv.health.gov.il
Cellular 0505324913
Work 972-4-6828943 Home 972-4-9885047
ACADEMIC DEGREES
1981 Hebrew University, Faculty of Medicine, Hadassah Medical
School, Jerusalem, Israel, MD
1996-1997 University of Haifa, Haifa Israel, Health Administration
2009 Clinical senior lecturer, Faculty of Medicine,Technion, Haifa.
2007-2009 Study for Master of Health Administration, University of Haifa,
Haifa, Not certified yet.
ACADEMIC APPOINTMENTS
1990- 1991 Instructor in Internal Medicine, Faculty of Medicine,Technion, Haifa.
2002-2003 Instructor in Internal Medicine, Faculty of Medicine,Technion, Haifa,
Internal Medicine department D, Rambam medical Center.
1991- 1992 Lecturer to nursing students (cardiology), Rambam Medical
Center School of Nursing, Haifa, Israel
1993-present Instructor to nursing students, Sieff Hospital School of
Nursing, Safed, Israel
PROFESSIONAL EXPERIENCE
1982-1983 Rotation Internship, Rambam Medical Center, Haifa, Israel
1987-1991 Resident, Internal Medicine 'D', Rambam Medical Center
Haifa, Israel.
a. 1992-1998 Senior Internist, Internal Medicine Dept., Sieff Government
b. hospital, Safed, Israel
1992- present Head of Lipid /Prevention of Atherosclerosis Unit, Outpatient
Clinics.
1993-1998 Head of Specialists' Qualification Review Committee.
1998-present Head of Internal Medicine Department (A).
RESEARCH INTERESTS
Atherosclerosis:
The place of oxidation and platelet activation on the atherogenesity of LDL:
Platelet secretory products in mice increase macrophage uptake of oxidized low density lipoprotein which promote foam cell formation as an early step in fatty streak genesis (1).
Moreover, the HMGCoA reductase inhibitors fluvastatin reduced platelet aggregation which was associated with altered platelet lipid composition and drug binding to the platelets (2).
Interactions of platelets, macrophages, and lipoproteins are contributory to the atherogenesity of hypercholesterolemia (3).
Anti-oxidant effect of hypolipidemic drugs:
Fluvastatin reduced susceptibility of LDL to lipid peroxidation which was associated with the hypocholesterolemic effect of the drug and its binding to the LDL (4).
Decreasing the time residency of LDL in the circulation can preserve its associated antioxidants thus protecting LDL from oxidation and thus decreasing its atherogenesity. This can be the mechanism by which cholestyramine can reduce susceptibility of LDL to lipid peroxidation in heterozygous familial hypercholesterolemic children (5).
HMGCoA reductase inhibitors demonstrated to have antiatherogenic properties mediated by its pleiotropic effects, such as antiplatelet effect and protecting LDL from oxidative modification.
In relation to the discussion about the place of ezetimibe as an antiatherogenic drug, ezetimibe have additive effect on the top of the HMGCoA reductase inhibitor simvastatin to protect LDL from peroxidation (6).
Hypertension:
Hypertension can be considered as a part of the metabolic disease. The question of treating high blood pressure or treating hypertension is still open. The good metabolic effects of antihypertensive therapies must be taken into consideration. ARB and ACE inhibitors can add antiatherogenic effect in hypertensive patients, on top of lowering blood pressure. Valsartan therapy has additive antioxidative effect to that of fluvastatin therapy against LDL oxidation (7). Lowering blood pressure by ACE inhibitor to the same extent as was done by combined treatment of ACE inhibitor and thiazide has the advantage of protecting LDL from peroxidation (8).
This can be one of the mechanisms by which new generations of blood pressure lowering drugs (CCB, ACE inhibitors and ARB's) do better than the old generations (BB, thiazides) in several recent studies.
Non-alcoholic steatohepatitis (NASH):
NASH is a prevalent component of the metabolic syndrome. Accumulation of triglycerides in the liver is driven by several mechanisms including dietary fat, type of the fatty acids, insulin resistance and others. Lowering fatty acids influx to the liver by orlistat treatment can improve NASH by laboratory and histologic parameters (9) Changing the group of dietary fatty acids in rats with NASH influence NASH disease activity (10) which can have clinical relevance in the dietary counseling for patients with NASH. The combined effect of insulin sensitizing agent's ezetimibe and valsartan in rats with non-alcoholic fatty liver disease drug therapy optimize the treatment of experimental NASH (11), as a therapeutic approach to this complex disease.
As part of the metabolic syndrome, elevated plasma protein C correlates with the presence of fatty liver (NASH and NAFLD) (12). Moreover, there is an association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. Thus NASH has a potential as a hypercoagulable disease (13).
The regenerative capacity of the liver from NASH patients is still conserved (14) and progression of fibrosis in experimental cirrhosis can be halted in rats (15), which can give hope for the reversibility, even partially, of advanced NASH disease.
Metabolic syndrome:
The Muslim Circassian community in Israel represents a unique population that is distinct from both Jews and Arabs with high prevalence of coronary artery disease. The homogeneous Circassian population, sharing the same environmental influences and having an endogamous pattern of marriage, suggest a role of genetic risk factors for diabetes (16). For that, Israeli Circassians are suitable for additional genetic studies that may lead to the identification of susceptibility genes for type 2 diabetes.
The high prevalence of CVD among Circassians was found to be etiologically unrelated to the three mutations that were studied in the genes for factor V, MTHFR, and prothrombin (17).
References:
Hussein O. Isr J Med Sci. 1993;29:453-9.
Hussein O. Br J Clin Pharmacol. 1997 Jul;44(1):77-83.
Aviram M. J Cardiovasc Pharmacol. 1998;31:39-45
Hussein O. Atherosclerosis. 1997;128:11-8.
Hussein O. Pathophysiology. 2001;8:21-28.
Hussein O. Br J Clin Pharmacol 2008;65:637-45.
Hussein O. J Cardiovasc Pharmacol. 2002;40:28-34.
Hussein O. Am J Hypertension 2003;16:734-8.
Hussein O. Dig Dis Sci 2007;52:2512-9.
Hussein O. World J Gastroenterol 2007;13:361-8.
Assy N. World J Gastroenterol 2006;12:4369-76.
Assy N. Gut 2005;54:729.
Assy N. World J Gastroenterol 2005;11:5834-39.
Hussein O. Dig Dis Science. 2002;47:1926-31.
Assy N. Dig Dis Sci 2007;52:1187-93.
Haron Y. IMAJ 2006;8:622-626.
Falik-Zaccai TC. Human Biol 2003;75:57-68.
TEACHING EXPERIENCE
Pharmacology, Faculty of Biotechnology, B.Sc, Tel – Hai College, 2002
Phamacology, graduate, Safed College.
Physiology of Cell, graduate, Safed College.
Instuctorof Biotechnology Engineer students,Ort Braude College,Karmiel.
1995-present: Supervisor of medical doctors at specialization, basic
sciences project, Sieff Hospital, Safed, Israel:
Dr Friedman G, Dr Weiner U, Dr Wasserman Y, Dr Lyan D,
Dr Sneider Y, Dr Radan A, Dr Gefen Y, Dr Schlisenger S,
Dr Menesian L, Dr Gefen H, Dr Nordkin Erena, Dr Itzkovith
Yeruslav, Rozman Alona, Dr. Abu Salech Jehad, Dr. Abu
Jabal Kamal.
ClLINICAL STUDIES
Principle investigator in 65 multicenter clinical trials.
GCP cource with successful participation in certification exam and membership in Association of Clinical Research Professionals since 2006.
MEMBERSHIP IN PROFESSIONAL SOCIETIES
1994 - European Atherosclerosis Society
1990 - Israeli Medical Association – Society for Research, Prevention and
Treatment of Atherosclerosis
1998 – Israeli Medical Association – Society for Internal Medicine
1996 - Israeli Society for Hypertension.
2009 International Society of Atherosclerosis
Research Experience
1994-1995: Research at the Lipid Research Unit, Rambam Medical Center, and
Technion Faculty of Medicine, Haifa.
1992-present:Lipid research laboratory, Research section, Sieff Hospital Safed.
PUBLIC PROFESSIONAL ACTIVITIES
1984-89 Military Service, IDF, as brigade physician, captain.
2002 Reserve Military Service, Commander of medical battalion,lieutenant
colonel.
2004-present Medical League for Health Progression and Education, president.
PUBLICATIONS
Refereed papers in professional journals
Basic:
1. Hussein O, Brook JG, Aviram M. Inhibition of cellular uptake of low-
density lipoprotein by mouse peritoneal macrophages that were pre- exposed in vivo to platelet secretory products. Harefuah. 1993 Mar 1;124(5):277-81. Hebrew.
2. Hussein O, Brook GJ, Aviram M. Intraperitoneal injection of platelet secretory products into mice increases macrophage uptake of oxidized low density lipoprotein. Isr J Med Sci. 1993;29:453-9.
3. Hussein O, Mira Rosenblat, Sorina Schlesinger, Shlomo Keidar, Michael
Aviram. Reduced platelet aggregation after fluvastatin therapy is
associated with altered platelet lipid composition and drug binding to the
platelets. Br J Clin Pharmacol. 1997 Jul;44(1):77-83.
4. Hussein O, Schlezinger S, Rosenblat M, Keidar S, Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis. 1997;128:11-8.
5. Aviram M, Hussein O, Rosenblat M, Schlezinger S, Hayek T, Keidar S. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol. 1998;31:39-45.
6. Hussein O, Frydman G, Frim H, Aviram M. Reduced susceptibility of low density lipoprotein to lipid peroxidation after cholestyramine treatment in heterozygous familial hypercholesterolemic children. Pathophysiology. 2001;8:21-28.
7. Hussein O, Schneider J, Rosenblat M, Aviram M. Valsartan therapy has additive antioxidative effect to that of fluvastatin therapy against LDL oxidation: studies in hypercholesterolemic and hypertensive patients. J Cardiovasc Pharmacol. 2002;40:28-34.
8. Hussein O, Radan A, Viskoper R. Effect of Cilazapril with or without low dose thiazide on LDL peroxidation in hypertensive patients. Am J Hypertension 2003;16:734-8.
9. Assy N, Grozovski M, Bersudsky I, Szalb S., Hussein O. Effect of insulin sensitizing agents in combination with ezetimibe and valsartan in rats with non-alcoholic fatty liver disease. World J Gastroenterol 2006;12:4369-76.
10. Hussein O, Grosovski M, Lasri E, Svalb S, Ravid U, Assy N. Monounsaturated fat decreases hepatic lipid content in nonalcoholic fatty liver disease in rats. World J Gastroenterol 2007;13:361-8.
11. Assy N, Hussein O, Abdallah K, Luder A, Svalb S, Paizi M, Spira G. The beneficial effect of aspirin and enoxaprin on fibrosis progression and regenerative activity in a rat model of cirrhosis. Dig Dis Sci 2007;52:1187-93.
Clinical:
1 Hussein O, Rosenblat M, Refael G, Aviram M. Dietary selenium increases
cellular glutathione peroxidase activity and reduces the enhanced
susceptibility to lipid peroxidation of plasma and low-density lipoprotein in
kidney transplant recipients. Transplantation1997;63:679-85.
2. Groshar D, Gorenberg M, Hussein O. Quantitative SPET 99Tcm-DMSA
uptake by the kidneys: age-related decline in healthy males. Nucl Med
Commun. 1998; 19:893-7.
3. Edoute Y, Hussein O, Malberger E, Yerushalmi R, Tibon-fisher O, Assy
N. Diagnostic accuracy of direct fine-needle aspiration of liver lesions:
A prospective study of 107 patients in peripheral community center with
limited technological capability. Arch Gastroenterohepatol2001;20:19-
24, (editorial20:14-8).
4. Hussein O, Svalb S, Van den Akker-Berman LM, Assy N. Liver
regeneration is not altered in patients with non alcoholic steato-
hepatitis (NASH) when compared to chronic hepatitis infection with
similar grade of inflammation. Dig Dis Science. 2002;47:1926-31.
5. Falik-Zaccai TC, Haron Y, Eilat D, Harash B, Golinker E, Hussein O,
Eisikovits R, Borochowitz Z, Linn S. Coronary heart disease among
Circassians in Israel is not associated with mutations in thrombophilia
genes. Human Biol 2003;75:57-68.
6. Zidan J, Hussein O, Basher W, Zohar S. Serum CA125: A tumor
marker for monitoring response to treatment and follow-up in patients
with non-Hodgkin’s lymphoma. The Oncologist 2004;9: 417-21.
7. Assy N, Hussein O. Peginterferon and lamivudine for hepatitis B. Letter
to the Editor. New Engl J Med 2004;351:27.
8. Assy N, Schlesinger S, Miron D, Hussein O. Cycling of antibiotics for
the prophylaxis of recurrent spontaneous bacterial peritonitis in
cirrhotic patient. World J Gastroenterol 2005;11:6407-6408.
9. Assy N, Schlesinger S, Hussein O. Elevated plasma protein C
correlates with the presence of fatty liver (NASH and NAFLD).
Gut 2005;54:729.
10. Assy N, Bekirov I, Mejritzky Y, Solomon. L, Szvalb S, Hussein O.
Association between thrombotic risk factors and extent of fibrosis in
patients with non-alcoholic fatty liver diseases. World J Gastroenterol
2005;11:5834-39.
11. Haron Y, Hussein O, Epshtein L, Eilat D, Harash B, Linn S. Type 2
diabetes among circassians in Israel. IMAJ 2006;8:622-626.
12. Assy N, Kayal m, Mejirisky Y, Gorenberg M, Hussein O, Schlesinger S.
The changes in renal function after a single dose of intravenous furosemide
in patients with compensated liver cirrhosis. BMC Gastroenterol
2006;29:6:39.
12. Hussein O, Gefen Y, Karochero E, Zidan J, Luder A, Assy N, Sror ES,
Aviram M. The Contribution of LDL Tendency to Peroxidation to Plasma
Hemoglobin A1c Level in Diabetic Patients,Clinica Chimica Acta
2007;377:114-8.
14. Hussein O, Schlesinger S, Svalb S, Assy N. Orlistat reverse fatty
infiltration and improves hepatic fibrosis in obese patients with non
alcoholic steatohepatitis (NASH). Dig Dis Sci 2007;52:2512-9.
15. Assy N, Hussein O, Abassi Z. Weight loss induced by orlistat reverse fatty
infiltration and improves hepatic fibrosis in obese patients with non alcoholic
steatohepatitis. Gut 2007;56:443-4.
16. Assy N, Gefen H, Schlesingr S, Hussein O. The beneficial effect of N-
acetylcysteine and ciprofloxacin therapy on the outcome of ischemic
fulminant hepatic failure. Dig Dis Sci 2007;52:3507-10.
17. Hussein O, Minasian L, Itzkovich Y, Shestatski K, Solomon L, Zidan J.
Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation
in hypercholesterolemia as monotherapy or in addition to simvastatin. Br J
Clin Pharmacol early release. 2008;65:637-45.
18. Zidan J, Hussein O, Abzah A, Tamam S, Farraj Z, Friedman E. Oral
premedication for the prevention of hypersensitivity reactions to paclitaxel.
Med Oncol 2008 Mar 25.
Review:
1. Hussein O, Traub YM. Triglycerides and atherosclerosis: update and
therapeutic recommendations. Harefuah. 1994;126:593-7. Review. Hebrew.
2. Hussein O, Traub YM. Should serum cholesterol be checked in
children? Harefuah. 1993;125:225-7. Review. Hebrew.
3. Hussein O, Levy Y, Brook G. Pulmonary involvement in Behcet's
disease. Harefuah. 1991;120:542-4. Review. Hebrew.
In preparation
1. Hussein O, Gefen H, Klein R, Pleich M, Shargorodsky M,
Solomon L, Confino K, Cimand M, Zimlichman R. Metabolic components in
coronary slow flow phenomenon. Coronary Artery Disease.
2. O.Hussein, K. Abu Gabal, Zidan M. Grozovski, I. Bersudsky, N. Assy, R.
Karry, M. Aviram. The effect of insulin sensitizers (rosiglitazone and
metformin), cholesterol absorption inhibitor (ezetimibe) and angiotensin
receptor blocker (valsartan) alone or in combination, on serum paraoxonase
(PON) activity and on liver PON activity and on PON2 and PON3 mRNA
expression in experimental rat non-alcoholic fatty liver disease.
Research reports or case reports
1. Miron D, Olshink A, Assy N, Zucker M, Efrat M, Hussein O. Plasmodium
Malaria and borrelia co-infection. J Travel Med 2004;11:115-6.
2. Assy N, Khair G, Schlesinger S, Hussein O. Severe cholestatic jaundice
in the eldery induced by low dose amiodarone. Dig Dis Sci 2004;49:450-2.
3. Assy N, Schlisenger S, Hussein O. Acute hepatitis with extremely high
ferritin levels and still’s disease. J Hepatology. 2001,35:830-31.
4. Hussein O, Finkelstein R, Brook JG. Rhabdomyolysis complicating
acute Epstein-Barr virus infection. Infection. 1995 Mar-Apr;23(2):119-20.
CONFERENCES
1. Hussein O, Levy Y, Markel A, Book GJ. Pulmonary Behcet's disease
presenting as fever of unknown origin. Behcet's disease. 5th International
Conference. Mayo Clinic, Rochester MN, 1989, pp 191-3.
2. Hussein O, Rosenblat M, Keidar S, Aviram. Fluvastatin and lovastatin
reduce platelet aggregation in hypercholesterolemic patients. IVth
Congress of the International Society on Thrombosis and Haemostasis.
Abs. 1995.
3. Spira G, Kraizer Y, Paizi M, Hussein O, Assy N. Vascular endothelial
growth factor and respective monoclonal antibodies can modulate liver cell
proliferation following partial hepatectomy in rats. Hepatology 1999,
AASLD.
4. Assy N, Gorenberg M, Awawdeh M, Lerman A, Hussein O. Clinical
implication of DMSA uptake by the kidneys in cirrhotic patients with
clinically normal renal function. Am Assoc for the Study of Liver Diseases,
September, 2001,Dallas (abs).
5. Assy N, Hussein O, Awawdeh M, Szvalb S, Spira G. The beneficial effect
of anti-thrombotic and anti-collagen drug combination on fibrosis
progression in a rat model of liver cirrhosis. Am Assoc for the Study of
Liver Diseases, September, Dallas (abs).
6. Haron Y, Hussein O, Shai L. “Cardiovascular risk factors of the Circassian
population in Israel”, XIIth International Symposium on Atherosclerosis,
June 25-29, 2000, Stockholm.
7. Haron Y, Hussein O, Shai L. “Insulin Resistance Syndrome and Obesity
in the Circassian Population in Israel”, XIIth International Symposium on
Atherosclerosis, June 25-29, 2000, Stockholm.
8. Hussein O, Assy N, Orlistat (Xenical) reverse fatty liver disease and
improve hepatic fibrosis in obese patients with NASH, 2003,
Dallas,USA
9. Hussein O, Schlesinger S, Svalb S, Assy N. Orlistat reverse fatty
infiltration and improves hepatic fibrosis in obese patients with NASH.
Atherosclerosis 2003, Eilat, Israel.
10. Assy N, Gorenberg M, Awawdeh M, Lerman A, Hussein O. Clinical
implication of DMSA uptake by the kidneys in cirrhotic patients with
clinically normal renal function. Hepatology 2001 (Boston).
11. Assy nimer, Kayal M, Mejirisky Y, Gorenberg M, Sorina Schlesinger,
Hussein O. The changes in renal function after a single dose of
intravenous furosemide in patients with compensated liver cirrhosis.
EASL, Berlin 2004.
12. Hussein O, Lasri E, Grosovski M, Svalb S, Assy N. Monounsaturated fat
decrease hepatic lipid content in NASH in rats. Atherosclerosis, Haifa 2004.
13. Hussein O, Gefen Y, Karochero E, Luder A, Assy N. The Contribution of
LDL Tendency to Peroxidation to Plasma Hemoglobin A1c Level in
Diabetic Patients. Atherosclerosis, Haifa 2004.
14. Assy n, Shynin I, Mejirisky Y, Shen-Orr, Mson T, Hussein O. Abnormal
IGF-1 response to GH administration in patients with NASH. IASL, Eilat,
2004.
15. Hussein Osamah, Gefen Hana, Klein Robert. , Pleich Michael,
Shargorodsky Marina, Solomon Leura, Confino Keren, Cimand Michal,
Zimlichman Reuven Metabolic Components in Coronary Slow Flow
Phenomenon. Eilat 2004.
16. Hussein O, Lasri E, Grosovski M, Svalb S, Assy N. Effect of different faty
acids on liver content of different free fatty acids. Drugs affecting lipid
metabolism, Venice 2004.
17. Assy N, Davidov V, Grozovski M, Mejirisky Y, Schlesinger S, Hussein O.
Elevated protein C predicts fatty liver (NAFLD or NASH) independently of
classic risk factors, metabolic syndrome and C-reactive protein. EASL
2006:000120.
18. Assy N, Grozovski M, Bersudsky I, Szalvb S, Hussein O. Effect of insulin
sensitizing agents, in combination with ezetimibe, and valsartan in rats with
metabolic syndrome and fatty liver. EASL 2006;000119.
19. O.Hussein, K. Abu Gabal, Zidan M. Grozovski, I. Bersudsky, N. Assy, R.
Karry, M. Aviram. The effect of insulin sensitizers (rosiglitazone and
metformin), cholesterol absorption inhibitor (ezetimibe) and angiotensin
receptor blocker (valsartan) alone or in combination, on serum paraoxonase
(PON) activity and on liver PON activity and on PON2 and PON3 mRNA
expression in experimental rat non-alcoholic fatty liver disease. DALM NY
2007.
Lectures:
1. Community family physicians, Safed 1996: Advances in treatment of hypercholesterolemia.
2. Society for research,prevention and treatment of atherosclerosis meeting March 1996: Fluvastatin therapy reduces platelet aggregation: Dual effect on platelet lipid composition and on drug binding, Elat.
3. Community family physicians and managers of Clalit clinics, Acre 1997: Advances in treatment of hypercholesterolemia.
4. Community family physicians: Megar 1998: Mechanisms for decreasing cardiovascular death by statins and the pleotropic effects.
5. Community family physicians, Nazareth 1998: The contribution of triglycerides and HDL to atherosclerosis.
6. Vasopeptidase inhibition and cardiovascular disease meeting: Nazareth 2000: Improving endothelial function and protecting target organs in the diabetic patient.
7. Atherosclerosis: clinical and nutritional aspects, Nazareth 2002: Advances in metabolic syndrome.
8. Community family physicians, Tiberias, 2003: Hypertension and cardiovascular and cerebral protection..
9. Advances in neurology, Safed, 2003: Primary and secondary prevention of stroke.
10. Meetings of the Israeli society of research, prevention and treatment of atherosclerosis: Haifa 2004: Monounsaturated fat decrease hepatic lipid content in NAFLD in rats.
11. Community family physicians, Nazareth 2004: Dyslipidemia: new targets and new means.
12. The Israeli society for obesity, Tel Aviv 2004: Monounsaturated fat decrease hepatic lipid content in NAFLD in rats.
13. Community family physicians: Kiryat Tivon, 2004: Habits of drug treatments in hypertension, The Israeli experience.
14. Community family physicians, Tiberias, 2005: The place of calcium channel blockers in the treatment of hypertension.
15. Haifa,2005: The academy of atherosclerosis: Aggressive treatment of hyperlipidemia: Myth or EBM?
16. Staff meeting, Porya hospital, Tiberias, 2005: Aggressive treatment in atherosclerosis.
17. Staff meeting, Rambam medical center, Haifa 2006: CPC.Community family physicians, Acre 2006: The safety of statin therapy and the new goals of LDL.
18. Staff meeting, Holy family hospital Nazareth 2006: Metabolic syndrome.
19. Type 1 diabates meeting, 2006, Safed:Cardiovascular complications of diabetes.
20. Israel association of the study of the liver, 2006:Effect of insulin sensitizing agents, in combination with ezetimibe and valsartan in rats with metabolic syndrome and fatty liver.
21. New standards for optimal cardiovascular risk management, The Israeli societies for hypertension and internal medicine, Kesarya 2006:Optimal targets of blood lipids and the gap between optimal and available.
22. Senior pharmacists forum, Tiberias 2007: Rimonobant, new approach for treatment of metabolic risk factors.
23. Community family physicians, The academy for atherosclerosis, Tiberias, 2007:
24. Community family physicians, Hedera, 2007: Cardiometabolic risk and the endocannabenoid system.
25. Community family physicians, Jerusalem 2007: Early benefits of high dose statins.
26. The Israeli society of research, prevention and treatment of atherosclerosis, Eilat 2007: The effect of insulin sensitizers (rosiglitazone and metformin), cholesterol absorption inhibitor (ezetimibe) and angiotensin receptor blocker (valsartan) alone or in combination, on serum paraoxonase (PON) activity and on liver PON activity and on PON2 and PON3 mRNA expression in experimental rat non-alcoholic fatty liver disease.
27. The forum of internal medicine departments heads, Tiberias 2007: The endothelial dysfunction.
28. Staff meeting, Carmel medical center, Haifa 2007: New approaches for metabolic syndrome therapy.
29. Clinical research meeting, Hertzlya, 2007: The unstable plaque.
30. Community family physicians, Beet Gabriel 2007: The contribution of insulin to glycemic control.
31. Therapeutic approach to obesity, hypertension and atherosclerosis: Cardiology in the community meeting, Ramot 2008:Metabolic syndrome is more than its components
32. The Israeli society of research, prevention and treatment of atherosclerosis, Dead sea,2008: The academy of atherosclerosis: The treatment of dyslipidemia; decreasing LDL vs increasing HDL.
33. Community family physicians, Tiberias 2008: Therapeutic approach to dyslipidemic patients.
34. Nursing meeting for organ transplants, Multicultural nursing, Safed 2008: The druze point of view; Druze philosophy and science.
35. The northern diabetic forum, Acre 2008: The targets of LDL in diabetes mellitus type 1 and 2.
36. Community family physicians, Nativ Hashayarah, 2008: Case studies in hypertension.
37. The academy for treatment of obesity, Haifa 2008: The pharmacologic approach for treatment.
38. The academy for treatment of obesity, Netanya, 2008: Obesity, dyslipidemia and the connection; the risk and the treatment.
39. Staff meeting, Ziv Medical center, Safed 2008: Proceedings in metabolic syndrome.
40. The forum of community cardiology, Netanya, 2008: Measuring the efficiency of pharmacologic treatment of dyslipidemia.
41. Fatty liver, hepatitis C and metabolic syndrome, Ramat Gan 2009:The contribution of fatty liver to metabolic syndrome and cardiovascular disease.
42. The Israeli society of research, prevention and treatment of atherosclerosis,
43. The society for obesity research and treatment, Tel Aviv 2009: The effect of ezetimibe on experimental fructose enriched diet induced NAFLD in rats on high cholestrol diet.
44. The arab population health on the time axis meeting, Nazareth, 4, November, 2009. Statin in the primary prevention.
|
 
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
